More amendments in store for the Building and Construction Industry Payments Act
By Michael Creedon and Laura FitzGerald
The Queensland government has unveiled a series of amendments to be made to the Building and Construction Industry Payments Act 2004 (BCIPA). The reforms, announced at the recent Property Council Downtown Breakfast, have been approved by the Cabinet and are intended to come into effect later this year.
The proposed amendments include the establishment of an Adjudication Registry within the Queensland Building and Construction Commission to administer the Act, monitor performance and appoint adjudicators; and the amendment of timeframes for making and responding to payment claims under the act…
Click on the link below to read the rest of the Minter Ellison briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Minter Ellison
News from The Lawyer
Briefings from Minter Ellison
Asia Region Funds Passport: draft rules a step towards a regional market for managed investment funds
The Asia Region Funds Passport will create a regional market for managed investment funds and give Australian fund managers an opportunity to increase their presence in Asia.
The Federal Court of Australia has dismissed the ACCC’s anti-competitive conduct case against Pfizer, finding that Pfizer did not breach the prohibition on misuse of market power.